Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant
- 1 December 1998
- Vol. 52 (6) , 1064-1069
- https://doi.org/10.1016/s0090-4295(98)00366-5
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- HISTOLOGICAL AND CLINICAL FINDINGS IN 896 CONSECUTIVE PROSTATES TREATED ONLY WITH RADICAL RETROPUBIC PROSTATECTOMYJournal of Urology, 1998
- OPTIMIZATION OF PROSTATE BIOPSY STRATEGY USING COMPUTER BASED ANALYSISJournal of Urology, 1997
- Pathological Characteristics and Prognosis of Nonpalpable and Palpable Prostate Cancers with a Hybritech Prostate Specific Antigen of 4 to 10 ng./mlJournal of Urology, 1996
- The Volume of Prostate Cancer in the Biopsy Specimen Cannot Reliably Predict the Quantity of Cancer in the Radical Prostatectomy Specimen on an Individual BasisJournal of Urology, 1995
- The Use of Age-Specific Reference Ranges for Serum Prostate Specific Anitgen in Men 60 years Old or OlderJournal of Urology, 1995
- Standardized in vitro mapping with multiple core biopsies of total prostatectomy specimens: localization and prediction of tumour volume and gradeBritish Journal of Urology, 1994
- Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volumeCancer, 1993
- Detection of Non‐palpable Prostate Cancer. A Mathematical and Laboratory ModelBritish Journal of Urology, 1993
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991
- Capsular Penetration in Prostate Cancer. Significance for Natural History and TreatmentThe American Journal of Surgical Pathology, 1990